ATL1102 Blockbuster drug in 2020 and a Coy maker.

ATL1102:This drug is going to be a Blockbuster drug 2020..and a Company maker.

Facts to consider:On Monday ANP will announce that dosing is completed on all 9 boys in the DMD trial.and that Safety and Tolerability has been achieved.•Data is also suggestive of an improvement in muscle function as assessed by the Performance of Upper Limb Test (PUL 2.0), where the majority of participants have demonstrated either improvements or no change in their PUL 2.0 scores from baseline after 24 weeks of dosing with ATL1102 (Clinical benefit)

Now take into consideration that both Sareptas drugs for DMD have no Clinical Benefits and have to prove to the FDA that they do. Yet Sarepta has a market of $6billion•

CD49d is clinically validated in Multiple Sclerosis and Crohns disease where antibody drugs to CD49d are used• There are several orphan indications (like DMD) where CD49d expression is important in disease processes, and whereCD49d appears to be a superior target• ANP could move directly into clinical studies based on existing preclinical.• ANP to progress in indications where there are ATL1102 platform (antisense) and target (CD49d)

DMD market $2 Billion..for ATL1102 is say 10% = $200 mill per annum x10 P/E ratio=$2 billion which is $4 per share...And this is only for 1 indication..Remember People: No other Pharma or Biotech is working in the CD49d space...In the World.